Metabolism in the Lymphatic Niche of CLL

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to understand how the lymphatic niche supports CLL cell growth and glycolytic activity. It includes adults with untreated CLL and examines biological features in the lymphatic environment without any experimental intervention. The investigation is centered on patterns of metabolism and disease biology in the lymphatic tissues of participants treated at Nice University Hospital. No treatment or interventional procedures are performed as part of the study, focusing on observational data collection. The findings may shed light on how the tumor microenvironment relates to disease progression and metabolic activity.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients for whom the diagnosis of CLL has been established cytologically and phenotypically (Matutes score)
* Patients over 18 years old
* Patients who have signed the non-objection form
* Untreated patients

Exclusion Criteria:

* Patient with a solid cancer that is progressive or in remission for less than 3 years
* HIV positive patients
* Patients with chronic active hepatitis B or C
* History of allogeneic transplant

Where it's running

• Nice University Hospital
  Nice, France Recruiting

Study contacts

• Study coordinator: Caroline Ruetsch-Chelli
• Email: ruetsch-chelli.c@chu-nice.fr
• Phone: 33492039016

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Rocbrutinib versus pirtobrutinib for adults with relapsed or refractory CLL/SLL after a covalent BTK inhibitor

  This compares rocbrutinib and pirtobrutinib to see which works better and is safer for adults whose CLL or SLL returned or didn't respond after a covalent BTK inhibitor.

  Recruiting at 6 sites Phase 3 Newave Pharmaceutical Inc · Skokie, Illinois and 6 other locations · NCT07342478

• BAFF-R CAR-T therapy for relapsed or refractory BAFF-R–positive B-cell lymphoma

  This trial will test whether a BAFF‑R–targeted CAR‑T cell therapy is safe and can help adults with relapsed or refractory BAFF‑R–positive B‑cell lymphomas (such as DLBCL, CLL, FL, MCL, or WM).

  Recruiting Phase 1/2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07259070

• Anti‑CD19 CAR‑T plus a BTK inhibitor for newly diagnosed high‑risk CLL/SLL

  We will try combining anti‑CD19 CAR‑T cells with a BTK inhibitor as first‑line treatment for people newly diagnosed with high‑risk CLL or SLL.

  Recruiting The Affiliated Hospital of Xuzhou Medical University · Xuzhou, Jiangsu · NCT07120633

• Epcoritamab given after 2nd-generation BTK inhibitors for CLL/SLL

  This trial will try giving subcutaneous epcoritamab for up to 12 cycles to adults with CLL/SLL who have been on a second‑generation BTK inhibitor for at least 12 months to see if it can deepen responses to a complete remission with undetectable MRD so therapy can be stopped.

  Recruiting Phase 2 University of Cincinnati · Cincinnati, Ohio · NCT07108998

• Finding the right dose of MB-CART2219.1 CAR‑T (targets CD19 and CD22) for relapsed B‑cell cancers

  This trial will test MB‑CART2219.1, a CAR‑T cell therapy that targets CD19 and CD22, in adults and children with relapsed or refractory B‑cell cancers to find a safe dose.

  Recruiting Phase 1 University Hospital Tuebingen · Tübingen, Baden-Wurttemberg and 1 other locations · NCT07108868

• Comparing BGB-16673 to standard treatments for chronic lymphocytic leukemia

  This study is testing a new treatment called BGB-16673 to see if it works better than standard options for people with chronic lymphocytic leukemia who have already tried other therapies.

  Recruiting at 132 sites Phase 3 BeOne Medicines · Jonesboro, Arkansas and 131 other locations · NCT06846671

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.